2380 completed. 2380 Phase 3, 288 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2380 | Completed 2380 |
| Phase 2 | 288 | Completed 288 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) Linaprazan glurate 50 mg Twice Daily (BID), Linaprazan Glurate 50 mg Once Daily (QD), Lansoprazole 30 mg Once Daily (QD) - GERD (Gastroesophageal Reflux Disease) | Phase 3 | Completed | Cinclus Pharma Holding AB | 523 | 2025-09-11 | 2026-10-21 |
| 3°C Saline Injection at the Duodenal Papilla to Prevent Post-ERCP Pancreatitis Topical Cold Sterile Saline Irrigation of the Duodenal Papilla (3°C), Standard ERCP (Usual Care) - Pancreatitis | Phase 2 / Phase 3 | Completed | Universidad Nacional de Colombia | 900 | 2025-08-26 | 2026-02-02 |
| Short Course Steroids in Alcohol Associated Hepatitis Prednisolone 40 mg - Alcoholic Hepatitis | Phase 3 | Completed | Asian Institute of Gastroenterology, India | 151 | 2025-04-07 | 2026-09-01 |
| Study of Bitopertin in Participants With EPP or XLP (APOLLO) Placebo, DISC-1459 - Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | Phase 3 | Completed | Disc Medicine, Inc | 183 | 2025-04-04 | 2026-10-09 |
| Alginate vs Sucralfate for GERD Symptomatic Relief Alginate, Sucralfate - GERD | Phase 2 / Phase 3 | Completed | CMH Lahore Medical College and Institute of Dentistry | 140 | 2025-04-01 | 2026-07-15 |
| Effects of Standardized Boswellia Carterii Extract on Irritable Bowel Syndrome Patients Boswellia carterii Extract, Educationntal program for IBS patie - Irritable Bowel Syndrome | Phase 2 / Phase 3 | Completed | Mansoura University | 60 | 2025-01-01 | 2026-05-08 |
| Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease Fexuprazan, Esomeprazole - Gastro Oesophageal Reflux Disease | Phase 3 | Completed | Universitas Indonesia | 145 | 2024-08-28 | 2026-08-24 |
| Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis Fecal microbiota transplantation - Liver Cirrhosis | Phase 3 | Completed | Cristian Ichim | 19 | 2024-08-05 | 2026-03-27 |
| A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. Elafibranor, Placebo - Primary Biliary Cholangitis | Phase 3 | Completed | Ipsen | 92 | 2024-07-09 | 2026-07-09 |
| 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication Vonoprazan, Amoxicillin, Clarithromycin - Helicobacter Pylori Infection, Gastritis | Phase 3 | Completed | Alexandria University | 326 | 2024-06-30 | 2025-02-11 |
| Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) Essential Amino Acid Supplement by Amino Co, Placebo - Hepatic Steatosis, NAFLD | Phase 3 | Completed | University of Colorado, Denver | 31 | 2024-06-18 | 2026-08-31 |
| Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents Mevac-A vaccine, Havrix 720 Junior - HAV, Hepatitis A | Phase 3 | Completed | Chiang Mai University | 120 | 2024-04-27 | 2025-05-04 |
| The Effects of Bromelain Supplement in Patients With Ulcerative Colitis Bromlein, Placebo - Ulcerative Colitis, Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Completed | National Nutrition and Food Technology Institute | 52 | 2024-04-20 | 2026-10-27 |
| A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) Survodutide, Placebo - Obesity, Non-Alcoholic SteatoHepatitis (NASH) | Phase 3 | Completed | Boehringer Ingelheim | 218 | 2024-04-02 | 2026-04-30 |
| A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants HRV PCV-free, IPV - Gastroenteritis | Phase 3 | Completed | GlaxoSmithKline | 400 | 2024-03-22 | 2025-10-22 |
| Prophylaxis Against Post-Endoscopic Retrograde Cholangio-Pancreatography Pancreatitis. Rectal Indometacin - Pancreatitis, ERCP | Phase 3 | Completed | Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo | 60 | 2024-03-04 | 2026-05-20 |
| Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis Tradipitant - Idiopathic Gastroparesis, Diabetic Gastroparesis | Phase 3 | Completed | Vanda Pharmaceuticals | 17 | 2024-01-09 | 2026-10-19 |
| Optimizing Early Nutrition Support in Severe Stroke-2 Trophic enteral feeding combined with supplemental parenteral nutrition, Full enteral feeding - Severe Stroke, Acute Stroke | Phase 3 | Completed | Wen Jiang-3 | 546 | 2023-12-20 | 2026-06-24 |
| INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP Dersimelagon, Placebo - Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | Phase 3 | Completed | Tanabe Pharma America, Inc. | 165 | 2023-12-11 | 2026-06-04 |
| A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis Mirikizumab IV, Mirikizumab SC - Ulcerative Colitis | Phase 3 | Completed | Eli Lilly and Company | 63 | 2023-11-22 | 2026-06-03 |
Showing 20 of 2380. Sign in to see all of them.
Colorectal Neoplasms (237) · Hepatitis C (231) · Hepatitis B (158) · Hepatitis C, Chronic (158) · Cystic Fibrosis (135) · Colitis, Ulcerative (123) · Crohn Disease (122) · Stomach Neoplasms (119) · Colonic Neoplasms (107) · Rectal Neoplasms (101) · Carcinoma, Hepatocellular (98) · Pancreatic Neoplasms (92) · Gastroesophageal Reflux (88) · Fibrosis (66) · Diphtheria (54)
Gastrointestinal Diseases (1212) · Liver Diseases (800) · Intestinal Diseases (799) · Digestive System Neoplasms (737) · Neoplasms by Site (735) · Neoplasms (729) · Pathological Conditions, Signs and Symptoms (649) · Infections (598) · Virus Diseases (522) · Blood-Borne Infections (513) · Communicable Diseases (512) · Hepatitis, Viral, Human (510) · Hepatitis (509) · Gastrointestinal Neoplasms (506)
Fluorouracil (159) · Ribavirin (158) · Leucovorin (112) · Oxaliplatin (105) · Capecitabine (79) · peginterferon alfa-2a (78) · Cisplatin (69) · Bevacizumab (58) · Irinotecan (58) · Gemcitabine (57) · ivacaftor (51) · peginterferon alfa-2b (45) · Mesalamine (43) · Esomeprazole (42) · Sofosbuvir (40)
Merck Sharp & Dohme LLC (81) · GlaxoSmithKline (77) · Gilead Sciences (64) · AbbVie (61) · Vertex Pharmaceuticals Incorporated (56) · Hoffmann-La Roche (45) · Takeda (45) · Bristol-Myers Squibb (44) · AstraZeneca (43) · Bausch Health Americas, Inc. (25) · Sanofi Pasteur, a Sanofi Company (25) · Shire (25) · Novartis Pharmaceuticals (22) · Sun Yat-sen University (22) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (21)
United States (874) · Canada (496) · France (475) · Germany (461) · United Kingdom (400) · Italy (371) · Spain (345) · Belgium (336) · Australia (332) · Poland (281) · South Korea (273) · China (263) · Japan (248) · Netherlands (216) · Russia (197)
PMID 37983082, PMID 33331662, PMID 30977945, PMID 29380251, PMID 30012435, PMID 30923816, PMID 31568620, PMID 36306483, PMID 19735233, PMID 29461687, PMID 30529905, PMID 29377566, PMID 29404492, PMID 31268130, PMID 32445184, PMID 33356421, PMID 21129076, PMID 28193518, PMID 30679026, PMID 31378656, PMID 37368103, PMID 20195905, PMID 20526599, PMID 21997132, PMID 25040192, PMID 25583164, PMID 26893500, PMID 27847279, PMID 29850873, PMID 30476584, PMID 30868245, PMID 31077827, PMID 31599001, PMID 32085892, PMID 32635680, PMID 32766762, PMID 32816215, PMID 32870265, PMID 32964215, PMID 33324993, PMID 33684552, PMID 34614208, PMID 34795131, PMID 35174470, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36336750, PMID 36342120, PMID 36509366
2015 (46), 2014 (41), 2016 (33), 2017 (32), 2018 (21), 2019 (20), 2004 (19), 2008 (19), 2009 (18), 2023 (16), 2005 (10), U10CA031946 (9), U10CA021115 (6), U10CA012027 (4), U10CA021661 (3)